| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With M | Erlangen, Essen | Phase I / Phase II | rekrutiert |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | Erlangen | Phase I | rekrutiert |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 | Bamberg, Köln, Deggendorf | Phase III | rekrutiert |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Plac | Amberg, Berlin, Bottrop | Phase III | rekrutiert |
| A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Tak | Heidelberg, Erlangen, Hannover | Phase III | rekrutiert |
| A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosu | Berlin, Düsseldorf, Erlangen | Phase III | rekrutiert |
| ACCESS Registry: A Post Market Follow-up Study to Monitor the Safety, Performance and Usability | Erlangen, Mönchengladbach, München | — | rekrutiert |
| Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochem | Freiburg im Breisgau, Stuttgart, Aachen | Phase III | rekrutiert |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination Wit | Dresden, Erlangen, Essen | Phase I / Phase II | rekrutiert |
| CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease | Erlangen | Phase I / Phase II | rekrutiert |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Heidelberg, Erlangen, Berlin | Phase II | rekrutiert |
| Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) | Baden-Baden, Heidelberg, Mannheim | — | rekrutiert |
| Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Loca | Aalen, Amberg, Aschaffenburg | Phase IV | rekrutiert |
| Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracra | Mannheim, Bad Neustadt an der Saale, Burgau | ohne Phasenangabe | rekrutiert |
| DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to C | Berlin, Bonn, Köln | Phase III | rekrutiert |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung | Berlin, Dresden, Erlangen | Phase II | rekrutiert |
| DEfeating PEnile CAncer-2 | Berlin, Dresden, Erlangen | ohne Phasenangabe | rekrutiert |
| Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell | Erfurt, Erlangen, Heidelberg | Phase II | rekrutiert |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antine | Erlangen | Phase I / Phase II | rekrutiert |
| GISAR German Interdisciplinary Sarcoma Registry | Tübingen, Erlangen, Bad Saarow | — | rekrutiert |
| GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, T | Frankfurt am Main, Aachen, Altenburg | — | rekrutiert |
| Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITIO | Heidelberg, Tübingen, Augsburg | Phase II | rekrutiert |
| German Dementia Registry | Heidelberg, Mannheim, Tübingen | — | rekrutiert |
| ITP Registry and Accompanying Biospecimen Collection | Aachen, Altenburg, Aschaffenburg | — | rekrutiert |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MAS | Berlin, Bochum, Köln | Phase III | rekrutiert |
| Neurovascular Product Surveillance Registry | Augsburg, Berlin, Bochum | — | rekrutiert |
| PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS | Baden-Baden, Pforzheim, Stuttgart | — | rekrutiert |
| Pridopidine Phase 3 Study in Huntington's Disease | Aachen, Bochum, Erlangen | Phase III | rekrutiert |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blin | Aachen, Aschaffenburg, Augsburg | Phase II | rekrutiert |
| Real World Data Collection on the INSPIRIS RESILIA Aortic Valve | Heidelberg, Bad Neustadt an der Saale, Erlangen | — | rekrutiert |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Inve | Aachen, Berlin, Chemnitz | Phase II / Phase III | rekrutiert |
| Smart and Fit for Kidney Transplantation | Erlangen | ohne Phasenangabe | rekrutiert |
| Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With U | Homburg, Lübeck, Erlangen | ohne Phasenangabe | rekrutiert |
| Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Bre | Bayreuth, Köln, Dresden | Phase I / Phase II | rekrutiert |
| Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or | Ulm, Erlangen, München | Phase I / Phase II | rekrutiert |
| THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for t | Dresden, Erlangen, Frankfurt am Main | ohne Phasenangabe | rekrutiert |
| The "Global Paradise System" Registry | Ahrweiler, Bad Krozingen, Berlin | — | rekrutiert |
| The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in I | Aachen, Amberg, Berlin | Phase III | rekrutiert |
| The DefiPace Study | Erlangen, Nürnberg, Würzburg | — | rekrutiert |
| Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed | Essen, Aachen, Augsburg | Phase II | rekrutiert |